Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

The Dell OptiPlex 7420 AIO is a compact desktop powered by Intel's 14th-Gen Raptor Lake processor, offering up to 64GB of RAM ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A budget is a monthly or annual plan that documents your income, tracks your expenses and leaves room for financial goals. Many, or all, of the products featured on this page are from our ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two ...

Notable and upcoming products include Vertex Pharmaceuticals’ (VRTX) Trikafta for cystic fibrosis, Pfizer’s (PFE) Xtandi for prostate cancer, AbbVie (ABBV) and Johnson & Johnson’s (JNJ) 7 Imbruvica, ...